Global Benign Prostatic Hyperplasia Market 2023 by Company, Regions, Type and Application, Forecast to 2029

January 2023 | 86 pages | ID: G1A2E9221874EN
GlobalInfoResearch

Abstracts

Benign prostatic hyperplasia (BPH) also known as benign prostatic hypertrophy is characterized by the unusual propagation of the prostatic cells, which causes difficulties like urinary retention and infections of the urinary tract. It is most common among the aging men population, primarily driving this market. On the basis of geographical analysis, the North American region is expected to retain its dominance in this market owing to better healthcare infrastructure, high healthcare expenditure on urological disorders, increased awareness in the society increasing the outpatients center and hospitals visits.

According to our (Global Info Research) latest study, the global Benign Prostatic Hyperplasia market size was valued at USD 10520 million in 2022 and is forecast to a readjusted size of USD 14410 million by 2029 with a CAGR of 4.6% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Benign Prostatic Hyperplasia market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Benign Prostatic Hyperplasia market size and forecasts, in consumption value ($ Million), 2018-2029

Global Benign Prostatic Hyperplasia market size and forecasts by region and country, in consumption value ($ Million), 2018-2029

Global Benign Prostatic Hyperplasia market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029

Global Benign Prostatic Hyperplasia market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Benign Prostatic Hyperplasia

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Benign Prostatic Hyperplasia market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott, Allergan, Astellas Pharma, Boehringer Ingelheim Pharma and Eli Lilly and Company, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Benign Prostatic Hyperplasia market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

• Drug Therapy
• Dialysis
• Others

Market segment by Application

• Hospitals
• Clinics

Market segment by players, this report covers

• Abbott
• Allergan
• Astellas Pharma
• Boehringer Ingelheim Pharma
• Eli Lilly and Company
• GlaxoSmithKline
• Merck
• Pfizer
• Sanofi

Market segment by regions, regional analysis covers

• North America (United States, Canada, and Mexico)
• Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
• South America (Brazil, Argentina and Rest of South America)
• Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Benign Prostatic Hyperplasia product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Benign Prostatic Hyperplasia, with revenue, gross margin and global market share of Benign Prostatic Hyperplasia from 2018 to 2023.

Chapter 3, the Benign Prostatic Hyperplasia competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Benign Prostatic Hyperplasia market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Benign Prostatic Hyperplasia.

Chapter 13, to describe Benign Prostatic Hyperplasia research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope of Benign Prostatic Hyperplasia
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Benign Prostatic Hyperplasia by Type
  1.3.1 Overview: Global Benign Prostatic Hyperplasia Market Size by Type: 2018 Versus 2022 Versus 2029
  1.3.2 Global Benign Prostatic Hyperplasia Consumption Value Market Share by Type in 2022
  1.3.3 Drug Therapy
  1.3.4 Dialysis
  1.3.5 Others
1.4 Global Benign Prostatic Hyperplasia Market by Application
  1.4.1 Overview: Global Benign Prostatic Hyperplasia Market Size by Application: 2018 Versus 2022 Versus 2029
  1.4.2 Hospitals
  1.4.3 Clinics
1.5 Global Benign Prostatic Hyperplasia Market Size & Forecast
1.6 Global Benign Prostatic Hyperplasia Market Size and Forecast by Region
  1.6.1 Global Benign Prostatic Hyperplasia Market Size by Region: 2018 VS 2022 VS 2029
  1.6.2 Global Benign Prostatic Hyperplasia Market Size by Region, (2018-2029)
  1.6.3 North America Benign Prostatic Hyperplasia Market Size and Prospect (2018-2029)
  1.6.4 Europe Benign Prostatic Hyperplasia Market Size and Prospect (2018-2029)
  1.6.5 Asia-Pacific Benign Prostatic Hyperplasia Market Size and Prospect (2018-2029)
  1.6.6 South America Benign Prostatic Hyperplasia Market Size and Prospect (2018-2029)
  1.6.7 Middle East and Africa Benign Prostatic Hyperplasia Market Size and Prospect (2018-2029)

2 COMPANY PROFILES

2.1 Abbott
  2.1.1 Abbott Details
  2.1.2 Abbott Major Business
  2.1.3 Abbott Benign Prostatic Hyperplasia Product and Solutions
  2.1.4 Abbott Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2018-2023)
  2.1.5 Abbott Recent Developments and Future Plans
2.2 Allergan
  2.2.1 Allergan Details
  2.2.2 Allergan Major Business
  2.2.3 Allergan Benign Prostatic Hyperplasia Product and Solutions
  2.2.4 Allergan Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2018-2023)
  2.2.5 Allergan Recent Developments and Future Plans
2.3 Astellas Pharma
  2.3.1 Astellas Pharma Details
  2.3.2 Astellas Pharma Major Business
  2.3.3 Astellas Pharma Benign Prostatic Hyperplasia Product and Solutions
  2.3.4 Astellas Pharma Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2018-2023)
  2.3.5 Astellas Pharma Recent Developments and Future Plans
2.4 Boehringer Ingelheim Pharma
  2.4.1 Boehringer Ingelheim Pharma Details
  2.4.2 Boehringer Ingelheim Pharma Major Business
  2.4.3 Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Product and Solutions
  2.4.4 Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2018-2023)
  2.4.5 Boehringer Ingelheim Pharma Recent Developments and Future Plans
2.5 Eli Lilly and Company
  2.5.1 Eli Lilly and Company Details
  2.5.2 Eli Lilly and Company Major Business
  2.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Product and Solutions
  2.5.4 Eli Lilly and Company Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2018-2023)
  2.5.5 Eli Lilly and Company Recent Developments and Future Plans
2.6 GlaxoSmithKline
  2.6.1 GlaxoSmithKline Details
  2.6.2 GlaxoSmithKline Major Business
  2.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Product and Solutions
  2.6.4 GlaxoSmithKline Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2018-2023)
  2.6.5 GlaxoSmithKline Recent Developments and Future Plans
2.7 Merck
  2.7.1 Merck Details
  2.7.2 Merck Major Business
  2.7.3 Merck Benign Prostatic Hyperplasia Product and Solutions
  2.7.4 Merck Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2018-2023)
  2.7.5 Merck Recent Developments and Future Plans
2.8 Pfizer
  2.8.1 Pfizer Details
  2.8.2 Pfizer Major Business
  2.8.3 Pfizer Benign Prostatic Hyperplasia Product and Solutions
  2.8.4 Pfizer Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2018-2023)
  2.8.5 Pfizer Recent Developments and Future Plans
2.9 Sanofi
  2.9.1 Sanofi Details
  2.9.2 Sanofi Major Business
  2.9.3 Sanofi Benign Prostatic Hyperplasia Product and Solutions
  2.9.4 Sanofi Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2018-2023)
  2.9.5 Sanofi Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Benign Prostatic Hyperplasia Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
  3.2.1 Market Share of Benign Prostatic Hyperplasia by Company Revenue
  3.2.2 Top 3 Benign Prostatic Hyperplasia Players Market Share in 2022
  3.2.3 Top 6 Benign Prostatic Hyperplasia Players Market Share in 2022
3.3 Benign Prostatic Hyperplasia Market: Overall Company Footprint Analysis
  3.3.1 Benign Prostatic Hyperplasia Market: Region Footprint
  3.3.2 Benign Prostatic Hyperplasia Market: Company Product Type Footprint
  3.3.3 Benign Prostatic Hyperplasia Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Benign Prostatic Hyperplasia Consumption Value and Market Share by Type (2018-2023)
4.2 Global Benign Prostatic Hyperplasia Market Forecast by Type (2024-2029)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Benign Prostatic Hyperplasia Consumption Value Market Share by Application (2018-2023)
5.2 Global Benign Prostatic Hyperplasia Market Forecast by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Benign Prostatic Hyperplasia Consumption Value by Type (2018-2029)
6.2 North America Benign Prostatic Hyperplasia Consumption Value by Application (2018-2029)
6.3 North America Benign Prostatic Hyperplasia Market Size by Country
  6.3.1 North America Benign Prostatic Hyperplasia Consumption Value by Country (2018-2029)
  6.3.2 United States Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  6.3.3 Canada Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  6.3.4 Mexico Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)

7 EUROPE

7.1 Europe Benign Prostatic Hyperplasia Consumption Value by Type (2018-2029)
7.2 Europe Benign Prostatic Hyperplasia Consumption Value by Application (2018-2029)
7.3 Europe Benign Prostatic Hyperplasia Market Size by Country
  7.3.1 Europe Benign Prostatic Hyperplasia Consumption Value by Country (2018-2029)
  7.3.2 Germany Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  7.3.3 France Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  7.3.4 United Kingdom Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  7.3.5 Russia Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  7.3.6 Italy Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)

8 ASIA-PACIFIC

8.1 Asia-Pacific Benign Prostatic Hyperplasia Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Benign Prostatic Hyperplasia Market Size by Region
  8.3.1 Asia-Pacific Benign Prostatic Hyperplasia Consumption Value by Region (2018-2029)
  8.3.2 China Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  8.3.3 Japan Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  8.3.4 South Korea Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  8.3.5 India Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  8.3.6 Southeast Asia Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  8.3.7 Australia Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)

9 SOUTH AMERICA

9.1 South America Benign Prostatic Hyperplasia Consumption Value by Type (2018-2029)
9.2 South America Benign Prostatic Hyperplasia Consumption Value by Application (2018-2029)
9.3 South America Benign Prostatic Hyperplasia Market Size by Country
  9.3.1 South America Benign Prostatic Hyperplasia Consumption Value by Country (2018-2029)
  9.3.2 Brazil Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  9.3.3 Argentina Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Benign Prostatic Hyperplasia Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Country
  10.3.1 Middle East & Africa Benign Prostatic Hyperplasia Consumption Value by Country (2018-2029)
  10.3.2 Turkey Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  10.3.3 Saudi Arabia Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)
  10.3.4 UAE Benign Prostatic Hyperplasia Market Size and Forecast (2018-2029)

11 MARKET DYNAMICS

11.1 Benign Prostatic Hyperplasia Market Drivers
11.2 Benign Prostatic Hyperplasia Market Restraints
11.3 Benign Prostatic Hyperplasia Trends Analysis
11.4 Porters Five Forces Analysis
  11.4.1 Threat of New Entrants
  11.4.2 Bargaining Power of Suppliers
  11.4.3 Bargaining Power of Buyers
  11.4.4 Threat of Substitutes
  11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
  11.5.1 Influence of COVID-19
  11.5.2 Influence of Russia-Ukraine War

12 INDUSTRY CHAIN ANALYSIS

12.1 Benign Prostatic Hyperplasia Industry Chain
12.2 Benign Prostatic Hyperplasia Upstream Analysis
12.3 Benign Prostatic Hyperplasia Midstream Analysis
12.4 Benign Prostatic Hyperplasia Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Benign Prostatic Hyperplasia Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Benign Prostatic Hyperplasia Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Benign Prostatic Hyperplasia Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Benign Prostatic Hyperplasia Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Abbott Company Information, Head Office, and Major Competitors
Table 6. Abbott Major Business
Table 7. Abbott Benign Prostatic Hyperplasia Product and Solutions
Table 8. Abbott Benign Prostatic Hyperplasia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Abbott Recent Developments and Future Plans
Table 10. Allergan Company Information, Head Office, and Major Competitors
Table 11. Allergan Major Business
Table 12. Allergan Benign Prostatic Hyperplasia Product and Solutions
Table 13. Allergan Benign Prostatic Hyperplasia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Allergan Recent Developments and Future Plans
Table 15. Astellas Pharma Company Information, Head Office, and Major Competitors
Table 16. Astellas Pharma Major Business
Table 17. Astellas Pharma Benign Prostatic Hyperplasia Product and Solutions
Table 18. Astellas Pharma Benign Prostatic Hyperplasia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Astellas Pharma Recent Developments and Future Plans
Table 20. Boehringer Ingelheim Pharma Company Information, Head Office, and Major Competitors
Table 21. Boehringer Ingelheim Pharma Major Business
Table 22. Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Product and Solutions
Table 23. Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Boehringer Ingelheim Pharma Recent Developments and Future Plans
Table 25. Eli Lilly and Company Company Information, Head Office, and Major Competitors
Table 26. Eli Lilly and Company Major Business
Table 27. Eli Lilly and Company Benign Prostatic Hyperplasia Product and Solutions
Table 28. Eli Lilly and Company Benign Prostatic Hyperplasia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Eli Lilly and Company Recent Developments and Future Plans
Table 30. GlaxoSmithKline Company Information, Head Office, and Major Competitors
Table 31. GlaxoSmithKline Major Business
Table 32. GlaxoSmithKline Benign Prostatic Hyperplasia Product and Solutions
Table 33. GlaxoSmithKline Benign Prostatic Hyperplasia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. GlaxoSmithKline Recent Developments and Future Plans
Table 35. Merck Company Information, Head Office, and Major Competitors
Table 36. Merck Major Business
Table 37. Merck Benign Prostatic Hyperplasia Product and Solutions
Table 38. Merck Benign Prostatic Hyperplasia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Merck Recent Developments and Future Plans
Table 40. Pfizer Company Information, Head Office, and Major Competitors
Table 41. Pfizer Major Business
Table 42. Pfizer Benign Prostatic Hyperplasia Product and Solutions
Table 43. Pfizer Benign Prostatic Hyperplasia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Pfizer Recent Developments and Future Plans
Table 45. Sanofi Company Information, Head Office, and Major Competitors
Table 46. Sanofi Major Business
Table 47. Sanofi Benign Prostatic Hyperplasia Product and Solutions
Table 48. Sanofi Benign Prostatic Hyperplasia Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Sanofi Recent Developments and Future Plans
Table 50. Global Benign Prostatic Hyperplasia Revenue (USD Million) by Players (2018-2023)
Table 51. Global Benign Prostatic Hyperplasia Revenue Share by Players (2018-2023)
Table 52. Breakdown of Benign Prostatic Hyperplasia by Company Type (Tier 1, Tier 2, and Tier 3)
Table 53. Market Position of Players in Benign Prostatic Hyperplasia, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 54. Head Office of Key Benign Prostatic Hyperplasia Players
Table 55. Benign Prostatic Hyperplasia Market: Company Product Type Footprint
Table 56. Benign Prostatic Hyperplasia Market: Company Product Application Footprint
Table 57. Benign Prostatic Hyperplasia New Market Entrants and Barriers to Market Entry
Table 58. Benign Prostatic Hyperplasia Mergers, Acquisition, Agreements, and Collaborations
Table 59. Global Benign Prostatic Hyperplasia Consumption Value (USD Million) by Type (2018-2023)
Table 60. Global Benign Prostatic Hyperplasia Consumption Value Share by Type (2018-2023)
Table 61. Global Benign Prostatic Hyperplasia Consumption Value Forecast by Type (2024-2029)
Table 62. Global Benign Prostatic Hyperplasia Consumption Value by Application (2018-2023)
Table 63. Global Benign Prostatic Hyperplasia Consumption Value Forecast by Application (2024-2029)
Table 64. North America Benign Prostatic Hyperplasia Consumption Value by Type (2018-2023) & (USD Million)
Table 65. North America Benign Prostatic Hyperplasia Consumption Value by Type (2024-2029) & (USD Million)
Table 66. North America Benign Prostatic Hyperplasia Consumption Value by Application (2018-2023) & (USD Million)
Table 67. North America Benign Prostatic Hyperplasia Consumption Value by Application (2024-2029) & (USD Million)
Table 68. North America Benign Prostatic Hyperplasia Consumption Value by Country (2018-2023) & (USD Million)
Table 69. North America Benign Prostatic Hyperplasia Consumption Value by Country (2024-2029) & (USD Million)
Table 70. Europe Benign Prostatic Hyperplasia Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Europe Benign Prostatic Hyperplasia Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Europe Benign Prostatic Hyperplasia Consumption Value by Application (2018-2023) & (USD Million)
Table 73. Europe Benign Prostatic Hyperplasia Consumption Value by Application (2024-2029) & (USD Million)
Table 74. Europe Benign Prostatic Hyperplasia Consumption Value by Country (2018-2023) & (USD Million)
Table 75. Europe Benign Prostatic Hyperplasia Consumption Value by Country (2024-2029) & (USD Million)
Table 76. Asia-Pacific Benign Prostatic Hyperplasia Consumption Value by Type (2018-2023) & (USD Million)
Table 77. Asia-Pacific Benign Prostatic Hyperplasia Consumption Value by Type (2024-2029) & (USD Million)
Table 78. Asia-Pacific Benign Prostatic Hyperplasia Consumption Value by Application (2018-2023) & (USD Million)
Table 79. Asia-Pacific Benign Prostatic Hyperplasia Consumption Value by Application (2024-2029) & (USD Million)
Table 80. Asia-Pacific Benign Prostatic Hyperplasia Consumption Value by Region (2018-2023) & (USD Million)
Table 81. Asia-Pacific Benign Prostatic Hyperplasia Consumption Value by Region (2024-2029) & (USD Million)
Table 82. South America Benign Prostatic Hyperplasia Consumption Value by Type (2018-2023) & (USD Million)
Table 83. South America Benign Prostatic Hyperplasia Consumption Value by Type (2024-2029) & (USD Million)
Table 84. South America Benign Prostatic Hyperplasia Consumption Value by Application (2018-2023) & (USD Million)
Table 85. South America Benign Prostatic Hyperplasia Consumption Value by Application (2024-2029) & (USD Million)
Table 86. South America Benign Prostatic Hyperplasia Consumption Value by Country (2018-2023) & (USD Million)
Table 87. South America Benign Prostatic Hyperplasia Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Middle East & Africa Benign Prostatic Hyperplasia Consumption Value by Type (2018-2023) & (USD Million)
Table 89. Middle East & Africa Benign Prostatic Hyperplasia Consumption Value by Type (2024-2029) & (USD Million)
Table 90. Middle East & Africa Benign Prostatic Hyperplasia Consumption Value by Application (2018-2023) & (USD Million)
Table 91. Middle East & Africa Benign Prostatic Hyperplasia Consumption Value by Application (2024-2029) & (USD Million)
Table 92. Middle East & Africa Benign Prostatic Hyperplasia Consumption Value by Country (2018-2023) & (USD Million)
Table 93. Middle East & Africa Benign Prostatic Hyperplasia Consumption Value by Country (2024-2029) & (USD Million)
Table 94. Benign Prostatic Hyperplasia Raw Material
Table 95. Key Suppliers of Benign Prostatic Hyperplasia Raw Materials

List Of Figures

LIST OF FIGURES

Figure 1. Benign Prostatic Hyperplasia Picture
Figure 2. Global Benign Prostatic Hyperplasia Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Benign Prostatic Hyperplasia Consumption Value Market Share by Type in 2022
Figure 4. Drug Therapy
Figure 5. Dialysis
Figure 6. Others
Figure 7. Global Benign Prostatic Hyperplasia Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. Benign Prostatic Hyperplasia Consumption Value Market Share by Application in 2022
Figure 9. Hospitals Picture
Figure 10. Clinics Picture
Figure 11. Global Benign Prostatic Hyperplasia Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Benign Prostatic Hyperplasia Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Market Benign Prostatic Hyperplasia Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 14. Global Benign Prostatic Hyperplasia Consumption Value Market Share by Region (2018-2029)
Figure 15. Global Benign Prostatic Hyperplasia Consumption Value Market Share by Region in 2022
Figure 16. North America Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 17. Europe Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 18. Asia-Pacific Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 19. South America Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 20. Middle East and Africa Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 21. Global Benign Prostatic Hyperplasia Revenue Share by Players in 2022
Figure 22. Benign Prostatic Hyperplasia Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 23. Global Top 3 Players Benign Prostatic Hyperplasia Market Share in 2022
Figure 24. Global Top 6 Players Benign Prostatic Hyperplasia Market Share in 2022
Figure 25. Global Benign Prostatic Hyperplasia Consumption Value Share by Type (2018-2023)
Figure 26. Global Benign Prostatic Hyperplasia Market Share Forecast by Type (2024-2029)
Figure 27. Global Benign Prostatic Hyperplasia Consumption Value Share by Application (2018-2023)
Figure 28. Global Benign Prostatic Hyperplasia Market Share Forecast by Application (2024-2029)
Figure 29. North America Benign Prostatic Hyperplasia Consumption Value Market Share by Type (2018-2029)
Figure 30. North America Benign Prostatic Hyperplasia Consumption Value Market Share by Application (2018-2029)
Figure 31. North America Benign Prostatic Hyperplasia Consumption Value Market Share by Country (2018-2029)
Figure 32. United States Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 33. Canada Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 34. Mexico Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 35. Europe Benign Prostatic Hyperplasia Consumption Value Market Share by Type (2018-2029)
Figure 36. Europe Benign Prostatic Hyperplasia Consumption Value Market Share by Application (2018-2029)
Figure 37. Europe Benign Prostatic Hyperplasia Consumption Value Market Share by Country (2018-2029)
Figure 38. Germany Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 39. France Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 40. United Kingdom Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 41. Russia Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 42. Italy Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 43. Asia-Pacific Benign Prostatic Hyperplasia Consumption Value Market Share by Type (2018-2029)
Figure 44. Asia-Pacific Benign Prostatic Hyperplasia Consumption Value Market Share by Application (2018-2029)
Figure 45. Asia-Pacific Benign Prostatic Hyperplasia Consumption Value Market Share by Region (2018-2029)
Figure 46. China Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 47. Japan Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 48. South Korea Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 49. India Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 50. Southeast Asia Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 51. Australia Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 52. South America Benign Prostatic Hyperplasia Consumption Value Market Share by Type (2018-2029)
Figure 53. South America Benign Prostatic Hyperplasia Consumption Value Market Share by Application (2018-2029)
Figure 54. South America Benign Prostatic Hyperplasia Consumption Value Market Share by Country (2018-2029)
Figure 55. Brazil Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 56. Argentina Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 57. Middle East and Africa Benign Prostatic Hyperplasia Consumption Value Market Share by Type (2018-2029)
Figure 58. Middle East and Africa Benign Prostatic Hyperplasia Consumption Value Market Share by Application (2018-2029)
Figure 59. Middle East and Africa Benign Prostatic Hyperplasia Consumption Value Market Share by Country (2018-2029)
Figure 60. Turkey Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 61. Saudi Arabia Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 62. UAE Benign Prostatic Hyperplasia Consumption Value (2018-2029) & (USD Million)
Figure 63. Benign Prostatic Hyperplasia Market Drivers
Figure 64. Benign Prostatic Hyperplasia Market Restraints
Figure 65. Benign Prostatic Hyperplasia Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia in 2022
Figure 68. Manufacturing Process Analysis of Benign Prostatic Hyperplasia
Figure 69. Benign Prostatic Hyperplasia Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source